Shasun Pharmaceuticals estimates a loss of Rs 50 crore from the closure of its Cuddalore plant due to a chemical leak two weeks ago. The plant which makes anti-ulcerant drugs such as Ranitidine, Nizatidine and Gabapentin, expects to start operations in a day or two.
The drug maker reported a profit of Rs 37 lakh on flat revenue of Rs 145 crore for the third quarter ending December 31, 2010. For the preceding quarter ending September 30, 2010, Shasun reported a loss of Rs 5.5 crore on a turnover of Rs 147 crore.crackcrack
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1670.10 |
| Dr. Reddys Lab | 1223.40 |
| Cipla | 1232.65 |
| Zydus Lifesciences | 932.25 |
| Lupin | 2327.55 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: